Immune response recalibration using immune therapy and biomimetic nano-therapy against high-grade gliomas and brain metastases

Abstract

Although with aggressive standards of care like surgical resection, chemotherapy, and radiation, high-grade gliomas (HGGs) and brain metastases (BM) treatment has remained challenging for more than two decades. However, technological advances in this field and immunotherapeutic strategies have revolutionized the treatment of HGGs and BM. Immunotherapies like immune checkpoint inhibitors, CAR-T targeting, oncolytic virus-based therapy, bispecific antibody treatment, and vaccination approaches, etc., are emerging as promising avenues offering new hope in refining patient's survival benefits. However, selective trafficking across the blood-brain barrier (BBB), immunosuppressive tumor microenvironment (TME), metabolic alteration, and tumor heterogeneity limit the therapeutic efficacy of immunotherapy for HGGs and BM. Furthermore, to address this concern, the NanoBioTechnology-based bioinspired delivery system has been gaining tremendous attention in recent years. With technological advances such as Trojan horse targeting and infusing/camouflaging nanoparticles surface with biological molecules/cells like immunocytes, erythrocytes, platelets, glioma cell lysate and/or integrating these strategies to get hybrid membrane for homotypic recognition. These biomimetic nanotherapy offers advantages over conventional nanoparticles, focusing on greater target specificity, increased circulation stability, higher active loading capacity, BBB permeability (inherent inflammatory chemotaxis of neutrophils), decreased immunogenicity, efficient metabolism-based combinatorial effects, and prevention of tumor recurrence by induction of immunological memory, etc. provide new age of improved immunotherapies outcomes against HGGs and BM. In this review, we emphasize on neuro-immunotherapy and the versatility of these biomimetic nano-delivery strategies for precise targeting of hard-to-treat and most lethal HGGs and BM. Moreover, the challenges impeding the clinical translatability of these approaches were addressed to unmet medical needs of brain cancers.

Keywords

High-grade glioma / Brain metastases / Immunotherapy / Blood-brain-barrier / Biomimetic nanoparticles / Clinical translatability

Conflicts of interest

All the authors declared that the investigation was conducted in the absence of any financial/commercial interest that could be constructed as a potential conflict.

References

[1] Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro Oncol 2022; 24(5):1-95.

[2] Lin YY, Wang YC, Yeh DW, Hung CY, Yeh YC, Ho HL, et al. Gene expression profile in primary tumor is associated with brain-tropism of metastasis from lung adenocarcinoma. Int J Mol Sci 2021; 22(24):13374.

[3] Widodo SS, Dinevska M, Cuzcano L, Papanicolaou M, Cox TR, Stylli SS, et al. Spatial analysis of the metastatic brain tumor immune and extracellular matrix microenvironment. Adv Cancer Biol - Metastasis 2023; 7:100096.

[4] Wang Y, Chen R, Wa Y, Ding S, Yang Y, Liao J, et al. Tumor immune microenvironment and immunotherapy in brain metastasis from non-small cell lung cancer. Front Immunol 2022; 13:829451.

[5] Vishnoi M, Scranton RA, Asante SK, Rostomily RC. Basic biology of brain metastasis. In: Ramakrishna R, Magge R, Baaj A, Knisely J, Central nervous system metastases. Cham: Springer International Publishing; 2020. p. 19-35.

[6] Stitzlein LM, Adams JT, Stitzlein EN, Dudley RW, Chandra J. Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks. J Experiment Clin Cancer Res 2024; 43(1):12.

[7] Shah PP, White T, Khalafallah AM, Romo CG, Price C, Mukherjee D. A systematic review of tumor treating fields therapy for high-grade gliomas. J Neurooncol 2020; 148(3):433-43.

[8] Barthel L, Hadamitzky M, Dammann P, Schedlowski M, Sure U, Thakur BK, et al. Glioma: molecular signature and crossroads with tumor microenvironment. Canc Metastasis Rev 2022; 41(1):53-75.

[9] Zhou D, Gong Z, Wu D, Ma C, Hou L, Niu X, et al. Harnessing immunotherapy for brain metastases: insights into tumor-brain microenvironment interactions and emerging treatment modalities. J Hematol Oncol 2023; 16(1):121.

[10] Lin YJ, Mashouf LA, Lim M. CAR T cell therapy in primary brain tumors: current investigations and the future. Front Immunol 2022; 13:817296.

[11] Filippone A, Lanza M, Mannino D, Raciti G, Colarossi C, Sciacca D, et al. PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression. Cancer Immunol Immunother 2022; 71(9):2067-75.

[12] Yan Y, Zeng S, Gong Z, Xu Z. Clinical implication of cellular vaccine in glioma: current advances and future prospects. J Exp Clin Cancer Res 2020 Nov 23;39(1):257.

[13] Ahmad A, Khan P, Rehman AU, Batra SK, Nasser MW. Immunotherapy: an emerging modality to checkmate brain metastasis. Mol Cancer 2023; 22(1):111.

[14] Norris GT, Kipnis J. Immune cells and CNS physiology: microglia and beyond. J Experimental Med 2019; 216(1):60-70.

[15] Franson A, McClellan BL, Varela ML, Comba A, Syed MF, Banerjee K, et al. Development of immunotherapy for high-grade gliomas: overcoming the immunosuppressive tumor microenvironment. Front Med (Lausanne) 2022; 9:966458.

[16] Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Experiment Clinical Cancer Res 2021; 40(1):184.

[17] Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, et al. The role of tumor Necrosis factor alpha (TNF- a ) in autoimmune disease and current TNF- a inhibitors in therapeutics. Int J Mol Sci 2021; 22(5):2719.

[18] Chiquet M. Tenascin-C: from discovery to structure-function relationships. Front Immunol 2020; 11:611789.

[19] Li X, Yang Y, Zhang B, Lin X, Fu X, An Y, et al. Lactate metabolism in human health and disease. Signal Transduct Target Ther 2022; 7(1):305.

[20] Pearson JRD, Cuzzubbo S, McArthur S, Durrant LG, Adhikaree J, Tinsley CJ, et al. Immune escape in glioblastoma multiforme and the adaptation of immunotherapies for treatment. Front Immunol 2020; 11:582106.

[21] Bertolini F, Spallanzani A, Fontana A, Depenni R, Luppi G. Brain metastases: an overview. CNS Oncol 2015; 4(1):37-46.

[22] Prinz M, Masuda T, Wheeler MA, Quintana FJ. Microglia and central nervous system-associated macrophages-From origin to disease modulation. Annu Rev Immunol 2021; 39(1):251-77.

[23] Han Y, Liu D, Li L. PD-1/PD-L 1 pathway: current researches in cancer. Am J Cancer Res 2020; 10(3):727-42.

[24] Voicu IP, Pravatà E, Panara V, Navarra R, Mattei PA, Caulo M. Differentiating solitary brain metastases from high-grade gliomas with MR: comparing qualitative versus quantitative diagnostic strategies. Radiol Med 2022; 127(8):891-8.

[25] Zhai L, Lauing KL, Chang AL, Dey M, Qian J, Cheng Y, et al. The role of IDO in brain tumor immunotherapy. J Neurooncol 2015; 123(3):395-403.

[26] Tao JC, Yu D, Shao W, Zhou DR, Wang Y, Hou SQ, et al. Interactions between microglia and glioma in tumor microenvironment. Front Oncol 2023; 13:1236268.

[27] Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JPY, Baldwin AS. Akt-dependent regulation of NF- $\kappa$B is controlled by mTOR and raptor in association with IKK. Genes Dev 2008; 22(11):1490-500.

[28] Gong X, Hou Z, Endsley MP, Gronseth EI, Rarick KR, Jorns JM, et al. Interaction of tumor cells and astrocytes promotes breast cancer brain metastases through TGF- $\beta$2/ANGPTL 4 axes. NPJ Precis Oncol 2019; 3(1):24.

[29] Dabravolski SA, Andreeva ER, Eremin II, Markin AM, Nadelyaeva II, Orekhov AN, et al. The role of pericytes in regulation of innate and adaptive immunity. Biomedicines 2023; 11(2):600.

[30] Prillaman M. How cancer hijacks the nervous system to grow and spread. Nature 2024; 626(7997):22-4.

[31] Liu J, Geng X, Hou J, Wu G. New insights into M1/M2 macrophages: key modulators in cancer progression. Cancer Cell Int 2021; 21(1):389.

[32] Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol 2024; 8(1):31.

[33] Catalán D, Mansilla MA, Ferrier A, Soto L, Oleinika K, Aguillón JC, et al. Immunosuppressive mechanisms of regulatory B Cells. Front Immunol 2021; 12:611795.

[34] Baran J, Sobiepanek A, Mazurkiewicz-Pisarek A, Rogalska M, Gryciuk A, Kuryk L, et al. Mast cells as a target-A comprehensive review of recent therapeutic approaches. Cells 2023; 12(8):1187.

[35] Komi DEA, Redegeld FA. Role of mast cells in shaping the tumor microenvironment. Clin Rev Allergy Immunol 2020; 58(3):313-25.

[36] Desai R, Coxon AT, Dunn GP. Therapeutic applications of the cancer immunoediting hypothesis. Semin Cancer Biol 2022; 78:63-77.

[37] Lasek W. Cancer immunoediting hypothesis: history, clinical implications and controversies. Central Eur J Immunology 2022; 47(2):168-74.

[38] Zahir N, Sun R, Gallahan D, Gatenby RA, Curtis C. Characterizing the ecological and evolutionary dynamics of cancer. Nat Genet 2020; 52(8):759-67.

[39] Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Current Oncol 2022; 29(5):3044-60.

[40] Desland FA, Hormigo A. The CNS and the brain tumor microenvironment: implications for glioblastoma immunotherapy. Int J Mol Sci 2020; 21(19):7358.

[41] Yang M, Oh IY, Mahanty A, Jin WL, Yoo JS. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cancers (Basel) 2020; 12(9):2334.

[42] Ghouzlani A, Kandoussi S, Tall M, Reddy KP, Rafii S, Badou A. Immune checkpoint inhibitors in human glioma microenvironment. Front Immunol 2021; 12:679425.

[43] Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma. JAMA Oncol 2020; 6(7): 1003.

[44] Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med 2019; 25(3):470-6.

[45] Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 2019; 25(3):477-86.

[46] Sevenich L. Turning "cold" into "hot" tumors—Opportunities and challenges for radio-immunotherapy against primary and metastatic brain Cancers. Front Oncol 2019; 9:163.

[47] Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, et al. Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma. clinical cancer Research 2021; 27(4):1048-57.

[48] Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009; 229(1):12-26.

[49] Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 2020; 20(11):651-68.

[50] Vom Berg J, Vrohlings M, Haller S, Haimovici A, Kulig P, Sledzinska A, et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J Experimental Med 2013; 210(13):2803-11.

[51] Datsi A, Sorg RV. Dendritic cell vaccination of glioblastoma: road to success or dead End. Front Immunol 2021; 12:770390.

[52] Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, Kubota T, et al.A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neuroscience 2011; 18(8):1048-54.

[53] Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med 2023; 29(6):1370-8.

[54] Todo T.ATIM-14. Results of phase II clinical trial of oncolytic herpes virus G 47 △ in patients with glioblastoma. Neuro Oncol 2019; 21(Suppl 6):vi4.

[55] Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, et al. Intratumoral oncolytic herpes virus G47 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med 2022; 28(8):1630-9.

[56] Chandran SS, Klebanoff CA. T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunol Rev 2019; 290(1):127-47.

[57] McGranahan T, Therkelsen KE, Ahmad S, Nagpal S. Current state of immunotherapy for treatment of glioblastoma. Current Treat Options Oncol 2019; 20(3):24.

[58] Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med 2019; 25(3):462-9.

[59] Moserle L, Casanovas O. Anti-angiogenesis and metastasis: a tumour and stromal cell alliance. J Intern Med 2013; 273(2):128-37.

[60] Friebel E, Kapolou K, Unger S, Núñez NG, Utz S, Rushing EJ, et al. Single-cell mapping of Human brain cancer reveals tumor-specific instruction of tissue-invading Leukocytes. Cell 2020; 181(7):1626-42.

[61] Draghi A, Chamberlain CA, Furness A, Donia M. Acquired resistance to cancer immunotherapy. Semin Immunopathol 2019; 41(1):31-40.

[62] Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther 2021; 6(1):362.

[63] Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 2020; 5(1):28.

[64] Kawakami Y, Ohta S, Sayem MA, Tsukamoto N, Yaguchi T. Immune-resistant mechanisms in cancer immunotherapy. Int J Clin Oncol 2020; 25(5):810-7.

[65] Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 2018; 15(7):422-42.

[66] Liu Y, Chang Y, He X, Cai Y, Jiang H, Jia R, et al. CD47 enhances cell viability and migration ability but inhibits apoptosis in endometrial carcinoma cells via the PI3K/Akt/mTOR signaling pathway. Front Oncol 2020; 10:1525.

[67] Li F, Lv B, Liu Y, Hua T, Han J, Sun C, et al. Blocking the CD47-SIRP a axis by delivery of anti-CD 47 antibody induces antitumor effects in glioma and glioma stem cells. Oncoimmunology 2018; 7(2):e1391973.

[68] Hu J, Xiao Q, Dong M, Guo D, Wu X, Wang B. Glioblastoma immunotherapy targeting the innate immune checkpoint CD47-SIRP a axis. Front Immunol 2020; 11:593219.

[69] Brahmer J, Rasco D, Chen M, Masteller E, Qazi I, Rogers S, et al. Abstract B143: a phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers. Cancer Immunol Res 2016; 4(1):B143.

[70] Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med 2020; 26(1):39-46.

[71] Gschwandtner M, Derler R, Midwood KS. More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis. Front Immunol 2019; 10:2759.

[72] Lamano JB, Lamano JB, Li YD, DiDomenico JD, Choy W, Veliceasa D, et al. Glioblastoma-derived IL6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth. Clinical Cancer Res 2019; 25(12):3643-57.

[73] Yang F, He Z, Duan H, Zhang D, Li J, Yang H, et al. Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. Nat Commun 2021; 12(1):3424.

[74] Wu A, Maxwell R, Xia Y, Cardarelli P, Oyasu M, Belcaid Z, et al. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment. J Neurooncol 2019; 143(2):241-9.

[75] Amoozgar Z, Kloepper J, Ren J, Tay RE, Kazer SW, Kiner E, et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun 2021; 12(1):2582.

[76] Schneider JR, Kwan K, Boockvar JA. Missing naive T cells in the setting of glioblastoma are found to be sequestered in the bone marrow. Neurosurgery 2019; 85(2):E194-5.

[77] Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun 2021; 12(1):832.

[78] Zhang P, Rashidi A, Zhao J, Silvers C, Wang H, Castro B, et al. STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. Nat Commun 2023; 14(1):1610.

[79] Wang T, Zhang H, Han Y, Zheng Q Liu H, Han M, et al. Reversing T Cell dysfunction to boost glioblastoma immunotherapy by paroxetine-mediated GRK2 inhibition and blockade of multiple Checkpoints through biomimetic Nanoparticles. Adv Sci (Weinh) 2023; 10(9):e2204961.

[80] Weiss T, Schneider H, Silginer M, Steinle A, Pruschy M, Polić B, et al. NKG2D-dependent antitumor effects of chemotherapy and radiotherapy against glioblastoma. Clinical Cancer Res 2018; 24(4):882-95.

[81] Zhang L, Zhang Y, Wang X, Zhou Y, Qi J, Gu L, et al. A trojan-horse-like biomimetic nano-NK to elicit an immunostimulatory tumor microenvironment for enhanced GBM chemo-immunotherapy. Small 2023; 19(44):e2301439.

[82] Wang G, Zhong K, Wang Z, Zhang Z, Tang X, Tong A, et al. Tumor-associated microglia and macrophages in glioblastoma: from basic insights to therapeutic opportunities. Front Immunol 2022; 13:964898.

[83] Wu SY. The roles of microglia macrophages in tumor progression of brain cancer and metastatic disease. Front Bioscience 2017; 22(10):45-73.

[84] Wang Z, Zhong H, Liang X, Ni S. Targeting tumor-associated macrophages for the immunotherapy of glioblastoma: navigating the clinical and translational landscape. Front Immunol 2022; 13:1024921.

[85] Zhang F, Parayath NN, Ene CI, Stephan SB, Koehne AL, Coon ME, et al. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat Commun 2019; 10(1):3974.

[86] Şen Ö, Emanet M, Mazzuferi M, Bartolucci M, Catalano F, Prato M, et al. Microglia polarization and antiglioma effects fostered by dual cell membrane-coated doxorubicin-Loaded Hexagonal boron Nitride Nanoflakes. ACS Appl Mater Interfaces 2023; 15(50):58260-73.

[87] Cao Z, Liu X, Zhang W, Zhang K, Pan L, Zhu M, et al. Biomimetic macrophage membrane-camouflaged Nanoparticles induce ferroptosis by promoting mitochondrial damage in glioblastoma. ACS Nano 2023; 17(23):23746-60.

[88] Wang X, Ding H, Li Z, Peng Y, Tan H, Wang C, et al. Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects. Signal Transduct Target Ther 2022; 7(1):74.

[89] Miranda-Gonçalves V, Granja S, Martinho O, Honavar M, Pojo M, Costa BM, et al. Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas. Oncotarget 2016; 7(29):46335-53.

[90] Guyon J, Fernandez-Moncada I, Larrieu CM, Bouchez CL, Pagano Zottola AC, Galvis J, et al. Lactate dehydrogenases promote glioblastoma growth and invasion via a metabolic symbiosis. EMBO Mol Med 2022; 14(12):e15343.

[91] Chavarria V, Ortiz-Islas E, Salazar A, Pérez-de la Cruz V, Espinosa-Bonilla A, Figueroa R, et al. Lactate-loaded nanoparticles induce glioma cytotoxicity and increase the survival of rats bearing malignant glioma brain tumor. Pharmaceutics 2022; 14(2):327.

[92] Yan C, Yang Z, Chen P, Yeh Y, Sun C, Xie T, et al. GPR65 sensing tumor-derived lactate induces HMGB1 release from TAM via the CAMP/PKA/CREB pathway to promote glioma progression. J Experimental Clin Cancer Res 2024; 43(1):105.

[93] Lu G, Wang X, Li F, Wang S, Zhao J, Wang J, et al. Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma. Nat Commun 2022; 13(1):4214.

[94] Ke R, Zhen X, Wang HS, Li L, Wang H, Wang S, et al. Surface functionalized biomimetic bioreactors enable the targeted starvation-chemotherapy to glioma. J Colloid Interface Sci 2022; 609:307-19.

[95] Qiao L, Li X, Xiao Y, Yuan J, Yu D, Zuo M, et al. A component-optimized chemo-dynamic nanoagent for enhanced tumour cell-selective chemo-dynamic therapy with minimal side effects in a glioma mouse model. Biomater Sci 2022; 10(15):4170-83.

[96] Nan J, Yang W, Xie Y, Yu M, Chen Y, Zhang J. Emerging nano-immunotherapeutic approaches to glioma. Small Struct 2023; 4(8):2300016.

[97] Scheetz L, Kadiyala P, Sun X, Son S, Hassani Najafabadi A, Aikins M, et al. Synthetic high-density lipoprotein nanodiscs for personalized immunotherapy against gliomas. clinical cancer Research 2020; 26(16):4369-80.

[98] Liu H, Chen L, Liu J, Meng H, Zhang R, Ma L, et al. Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma. Cancer Lett 2017; 411:182-90.

[99] Mao C, Beiss V, Fields J, Steinmetz NF, Fiering S. Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent toll-like receptors. Biomaterials 2021; 275:120914.

[100] Kerstetter-Fogle A, Shukla S, Wang C, Beiss V, Harris PLR, Sloan AE, et al. Plant virus-like particle in situ vaccine for intracranial glioma immunotherapy. Cancers (Basel) 2019; 11(4):515.

[101] Beh CY, Prajnamitra RP, Chen LL, Hsieh PCH. Advances in biomimetic nanoparticles for targeted cancer therapy and diagnosis. Molecules 2021; 26(16):5052.

[102] Khera E, Dong S, Huang H, de Bever L, van Delft FL, Thurber GM. Cellular-resolution imaging of by stander payload tissue penetration from antibody-drug conjugates. Mol Cancer Ther 2022; 21(2):310-21.

[103] Anami Y, Otani Y, Xiong W, Ha SYY, Yamaguchi A, Rivera-Caraballo KA, et al. Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors. Cell Rep 2022; 39(8):110839.

[104] Mair MJ, Bartsch R, Le Rhun E, Berghoff AS, Brastianos PK, Cortes J, et al. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours. Nat Rev Clin Oncol 2023; 20(6):372-89.

[105] Guo P, Moses-Gardner A, Huang J, Smith ER, Moses MA. ITGA 2 as a potential nanotherapeutic target for glioblastoma. Sci Rep 2019; 9(1):6195.

[106] Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, et al. Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nat Commun 2019; 10(1):3850.

[107] Nuzzo S, Brancato V, Affinito A, Salvatore M, Cavaliere C, Condorelli G. The role of RNA and DNA aptamers in glioblastoma diagnosis and therapy: a systematic review of the Literature. Cancers (Basel) 2020; 12(8):2173.

[108] Tan X, Jia F, Wang P, Zhang K. Nucleic acid-based drug delivery strategies. J Control Release 2020; 323:240-52.

[109] Hegde MM, Prabhu S, Mutalik S, Chatterjee A, Goda JS. Satish Rao BS. Multifunctional lipidic nanocarriers for effective therapy of glioblastoma: recent advances in stimuli-responsive, receptor and subcellular targeted approaches. J Pharm Investig 2022; 52(1):49-74.

[110] Monaco I, Camorani S, Colecchia D, Locatelli E, Calandro P, Oudin A, et al. Aptamer functionalization of nanosystems for glioblastoma targeting through the blood-brain barrier. J Med Chem 2017; 60(10):4510-6.

[111] Shi S, Fu W, Lin S, Tian T, Li S, Shao X, et al. Targeted and effective glioblastoma therapy via aptamer-modified tetrahedral framework nucleic acid-paclitaxel nanoconjugates that can pass the blood brain barrier. Nanomedicine 2019; 21:102061.

[112] Tang J, Huang N, Zhang X, Zhou T, Tan Y, Pi J, et al. Aptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of glioma. Int J Nanomedicine 2017; 12:3899-911.

[113] Li F, Wang Y, Chen D, Du Y. Nanoparticle-based immunotherapy for reversing T-cell exhaustion. Int J Mol Sci 2024; 25(3):1396.

[114] Kang M, Hong J, Jung M, Kwon SP, Song SY, Kim HY, et al. T-cell-mimicking Nanoparticles for cancer immunotherapy. Advanced Materials 2020; 32(39):e2003368.

[115] Ma W, Zhu D, Li J, Chen X, Xie W, Jiang X, et al. Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment. Theranostics 2020; 10(3):1281-95.

[116] Tang L, Zheng Y, Melo MB, Mabardi L, Castaño AP, Xie YQ, et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol 2018; 36(8):707-16.

[117] Nie W, Wei W, Zuo L, Lv C, Zhang F, Lu GH, et al. Magnetic nanoclusters armed with responsive PD-1 antibody synergistically improved adoptive T-cell therapy for solid tumors. ACS Nano 2019; 13(2):1469-78.

[118] Balakrishnan PB, Sweeney EE. Nanoparticles for enhanced adoptive T cell therapies and future perspectives for CNS tumors. Front Immunol 2021; 12:600659.

[119] Kim GB, Aragon-Sanabria V, Randolph L, Jiang H, Reynolds JA, Webb BS, et al.High-affinity mutant interleukin-13 targeted CAR T cells enhance delivery of clickable biodegradable fluorescent nanoparticles to glioblastoma. Bioact Mater 2020; 5(3):624-35.

[120] Zhang P, Miska J, Lee-Chang C, Rashidi A, Panek WK, An S, et al. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma. Proceed Natl Acad Sci 2019; 116(47):23714-23.

[121] Schiffer D, Mellai M, Bovio E, Annovazzi L. The neuropathological basis to the functional role of microglia/macrophages in gliomas. Neurological Sciences 2017; 38(9):1571-7.

[122] Sandbhor P, Palkar P, Bhat S, John G, Goda JS. Nanomedicine as a multimodal therapeutic paradigm against cancer: on the way forward in advancing precision therapy. Nanoscale 2024; 16(13):6330-64.

[123] Wang T, Zhang H, Qiu W, Han Y, Liu H, Li Z. Biomimetic nanoparticles directly remodel immunosuppressive microenvironment for boosting glioblastoma immunotherapy. Bioact Mater 2022; 16:418-32.

[124] Yin Y, Tang W, Ma X, Tang L, Zhang Y, Yang M, et al. Biomimetic neutrophil and macrophage dual membrane-coated nanoplatform with orchestrated tumor-microenvironment responsive capability promotes therapeutic efficacy against glioma. Chemical Engineering J 2022; 433:133848.

[125] Gong P, Wang Y, Zhang P, Yang Z, Deng W, Sun Z, et al. Immunocyte membrane-coated Nanoparticles for cancer immunotherapy. Cancers (Basel) 2020; 13(1):77.

[126] Xue J, Zhao Z, Zhang L, Xue L, Shen S, Wen Y, et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat Nanotechnol 2017; 12(7):692-700.

[127] Ma X, Kuang L, Yin Y, Tang L, Zhang Y, Fan Q, et al. Tumor-antigen activated dendritic cell membrane-coated biomimetic Nanoparticles with orchestrating immune responses promote therapeutic efficacy against glioma. ACS Nano 2023; 17(3):2341-55.

[128] Deng G, Peng X, Sun Z, Zheng W, Yu J, Du L, et al. Natural-killer-cell-inspired nanorobots with aggregation-induced emission characteristics for near-infrared-II fluorescence-guided glioma theranostics. ACS Nano 2020; 14(9):11452-62.

[129] Shields CW, Evans MA, Wang LLW, Baugh N, Iyer S, Wu D, et al. Cellular backpacks for macrophage immunotherapy. Sci Adv 2020; 6(18):eaaz6579.

[130] Allami P, Heidari A, Rezaei N. The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma. Front Mol Biosci 2023; 9:1083645.

[131] De Pasquale D, Marino A, Tapeinos C, Pucci C, Rocchiccioli S, Michelucci E, et al. Homotypic targeting and drug delivery in glioblastoma cells through cell membrane-coated boron nitride nanotubes. Mater Des 2020; 192:108742.

[132] Wang Z, Zhang M, Chi S, Zhu M, Wang C, Liu Z. Brain tumor cell membrane-coated lanthanide-doped nanoparticles for NIR-IIb luminescence imaging and surgical navigation of glioma. Adv Healthc Mater 2022; 11(16):e2200521.

[133] Wang C, Wu B, Wu Y, Song X, Zhang S, Liu Z. Camouflaging Nanoparticles with brain metastatic tumor cell membranes: a new strategy to traverse blood-brain barrier for imaging and therapy of brain tumors. Adv Funct Mater 2020; 30(14):1909369.

[134] Ren Y, Miao C, Tang L, Liu Y, Ni P, Gong Y, et al. Homotypic cancer cell membranes camouflaged Nanoparticles for targeting drug delivery and enhanced chemo-photothermal therapy of glioma. Pharmaceuticals 2022; 15(2):157.

[135] Zhang G, Yao M, Ma S, Zhang K, Wang Y, Wang Z, et al. Application of cell membrane-functionalized biomimetic nanoparticles in the treatment of glioma. J Mater Chem B 2023; 11(30):7055-68.

[136] Li B, Chu T, Wei J, Zhang Y, Qi F, Lu Z, et al. Platelet-membrane-coated nanoparticles enable vascular disrupting agent combining anti-angiogenic drug for improved tumor vessel impairment. Nano Lett 2021; 21(6):2588-95.

[137] Wu L, Li Q, DengJ, Shen J, Xu W, Yang W, et al. Platelet-tumor cell hybrid membrane-camouflaged nanoparticles for enhancing therapy efficacy in glioma. Int J Nanomedicine 2021; 16:8433-46.

[138] Li Q, Shen J, Wu L, Lei S, Yang Y, Xu W, et al. Functional targeted therapy for glioma based on platelet membrane-coated nanogels. Cancer Nanotechnol 2023; 14(1):12.

[139] Chai Z, Hu X, Wei X, Zhan C, Lu L, Jiang K, et al. A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery. J Control Release 2017; 264:102-11.

[140] Liu X, Chen Y, Geng D, Li H, Jiang T, Luo Z, et al. Aptamer-modified erythrocyte membrane-coated pH -sensitive nanoparticles for c-met-targeted therapy of glioblastoma multiforme. Membranes (Basel) 2022; 12(8):744.

[141] Li M, Cui X, Wei F, Li C, Han X. RGD peptide modified erythrocyte membrane/porous nanoparticles loading Mir-137 for NIR-stimulated theranostics of glioblastomas. Nanomaterials 2022; 12(9):1464.

[142] Lin T, Zhao P, Jiang Y, Tang Y, Jin H, Pan Z, et al. Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS Nano 2016; 10(11):9999-10012.

[143] Berney E, Sabnis N, Panchoo M, Raut S, Dickerman R, Lacko AG. The SR-B1 receptor as a potential target for treating glioblastoma. J Oncol 2019; 2019:1-10.

[144] Park CR, Jo JH, Song MG, Park JY, Kim YH, Youn H, et al. Secreted protein acidic and rich in cysteine mediates active targeting of human serum albumin in U87MG xenograft mouse models. Theranostics 2019; 9(24):7447-57.

[145] Oliveira FD, Castanho MARB, Neves V. Exosomes and brain metastases: a review on their role and potential applications. Int J Mol Sci 2021; 22(19):10899.

[146] Zhang C, Song J, Lou L, Qi X, Zhao L, Fan B, et al. Doxorubicin-loaded nanoparticle coated with endothelial cells-derived exosomes for immunogenic chemotherapy of glioblastoma. Bioeng Transl Med 2025; 6(3):e10203.

[147] Li B, Chen X, Qiu W, Zhao R, Duan J, Zhang S, et al. Synchronous disintegration of ferroptosis defense axis via engineered exosome-conjugated magnetic nanoparticles for glioblastoma therapy. Advanced Science 2022; 9(17):e2105451.

[148] Monfared H, Jahangard Y, Nikkhah M, Mirnajafi-Zadeh J, Mowla SJ. Potential therapeutic effects of exosomes packed with a miR-21-sponge construct in a rat model of glioblastoma. Front Oncol 2019; 9:782.

[149] Mozhei OG, Teschemacher A, Kasparov S. Viral vectors as gene therapy agents for treatment of glioblastoma. Cancers (Basel) 2020; 12(12):3724.

[150] Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, et al. Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma. JAMA Oncol 2020; 6(12):1939.

[151] Xin X, Liu W, Zhang ZA, Han Y, Qi LL, Zhang YY, et al. Efficient anti-glioma therapy through the brain-targeted RVG15-modified liposomes loading paclitaxel-cholesterol complex. IntJ Nanomedicine 2021; 16:5755-76.

[152] Grafals-Ruiz N, Rios-Vicil CI, EL Lozada-Delgado, BI Quiñones-Díaz, Noriega-Rivera RA, Martínez-Zayas G, et al. Brain targeted gold liposomes improve RNAi delivery for glioblastoma. Int J Nanomedicine 2020; 15:2809-28

[153] Gupta MN, Roy I. How corona formation impacts nanomaterials as drug carriers. Mol Pharm 2020; 17(3):725-37.

[154] Wang H, Ding T, Guan J, Liu X, Wang J, Jin P, et al. Interrogation of folic acid-functionalized Nanomedicines: the regulatory roles of plasma proteins reexamined. ACS Nano 2020; 14(11):14779-89.

[155] Xiao W, Wang Y, Zhang H, Liu Y, Xie R, He X, et al. The protein corona hampers the transcytosis of transferrin-modified nanoparticles through blood-brain barrier and attenuates their targeting ability to brain tumor. Biomaterials 2021; 274:120888.

[156] Chen Z, Chen X, Huang J, Wang J, Wang Z. Harnessing protein corona for biomimetic Nanomedicine design. Biomimetics 2022; 7(3):126.

[157] Wu JY, Li YJ, Wang J, Hu XB, Huang S, Luo S, et al. Multifunctional exosome-mimetics for targeted anti-glioblastoma therapy by manipulating protein corona. J Nanobiotechnology 2021; 19(1):405.

[158] Zhang ZA, Xin X, Liu C, hong Liu Y, Duan HX, ling Qi L, et al. Novel brain-targeted nanomicelles for anti-glioma therapy mediated by the ApoE-enriched protein corona in vivo. J Nanobiotechnology 2021; 19(1):453.

[159] Pareja F, Macleod D, Shu C, Crary JF, Canoll PD, Ross AH, et al. PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and phospho-BAD. Molecular Cancer Res 2014; 12(7):987-1001.

[160] Moujalled D, Southon AG, Saleh E, Brinkmann K, Ke F, Iliopoulos M, et al. BH3 mimetic drugs cooperate with temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells. Cell Death Differ 2022; 29(7):1335-48.

[161] He W, Li X, Morsch M, Ismail M, Liu Y, Rehman FU, et al. Brain-targeted codelivery of Bcl-2/Bcl-xl and Mcl-1 inhibitors by biomimetic nanoparticles for orthotopic glioblastoma therapy. ACS Nano 2022; 16(4):6293-308.

[162] Wang S, Yang L, He W, Zheng M, Zou Y. Cell membrane camouflaged biomimetic Nanoparticles as a Versatile platform for brain diseases treatment. Small Methods 2024; 9(1):2400096.

[163] Yin T, Fan Q Hu F, Ma X, Yin Y, Wang B, et al. Engineered macrophage-membrane-coated nanoparticles with enhanced PD-1 expression induce immunomodulation for a synergistic and targeted anti glioblastoma activity. Nano Lett 2022; 22(16):6606-14.

[164] Lu H, Zhang S, Wang J, Chen Q. A review on polymer and Lipid-based Nanocarriers and its Application to Nano-pharmaceutical and food-based systems. Front Nutr 2021; 8:783831.

[165] Umemura Y, Orringer D, Junck L, Varela ML, West MEJ, Faisal SM, et al. Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial. Lancet Oncol 2023; 24(9):1042-52.

[166] Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 2017; 31(3):311-25.

[167] Wheeler LA, Manzanera AG, Bell SD, Cavaliere R, McGregor JM, Grecula JC, et al. Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. Neuro Oncol 2016; 18(8):1137-45.

[168] Cui J, Xu Y, Tu H, Zhao H, Wang H, Di L, et al. Gather wisdom to overcome barriers: well-designed nano-drug delivery systems for treating gliomas. Acta Pharm Sin B 2022; 12(3):1100-25.

[169] Kerklaan BM, Jager A, Aftimos P, Dieras V, Altintas S, Anders C, et al. NT-23: phase 1/2 A study of glutathione PEGylated liposomal doxorubicin (2B3-101) in breast cancer patients with brain metastases (BCBM) or recurrent high grade gliomas (HGG). Neuro Oncol 2014; 16(Suppl 5):v163.

[170] Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, et al. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Sci Transl Med 2021; 13(584):eabb3945.

[171] Kasenda B, König D, Manni M, Ritschard R, Duthaler U, Bartoszek E, et al. Targeting immunoliposomes to EGFR-positive glioblastoma. ESMO Open 2022; 7(1):100365.

[172] Umemura Y, Orringer D, Junck L, Heth J, Sagher O, Leung D, et al. A non-randomized, open-label, dose-finding, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injection. medRxiv 2022; 11(04):22281950.

[173] Arvanitis CD, Ferraro GB, Jain RK.The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer 2020; 20(1):26-41.

[174] Hersh AM, Alomari S, Tyler BM. Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology. Int J Mol Sci 2022; 23(8):4153.

[175] Wu H, Zhang T, Li N, Gao J. Cell membrane-based biomimetic vehicles for effective central nervous system target delivery: insights and challenges. J Control Rel 2023; 360:169-84.